Literature DB >> 11916484

Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra.

Ronald L Klein1, Michael A King, Mary E Hamby, Edwin M Meyer.   

Abstract

Somatic cell gene transfer was used to express a mutant form of alpha-synuclein (alpha-syn) that is associated with Parkinson's disease (PD) in the rat substantia nigra (SN), a brain region that, in humans, degenerates during PD. DNA encoding the A30P mutant of human alpha-syn linked to familial PD was incorporated into an adeno-associated virus vector, which was injected into the adult rat midbrain. The cytomegalovirus/chicken beta-actin promoter was used to drive transgene expression. Over a 1-year time course, this treatment produced three significant features relevant to PD: (1) accumulation of alpha-syn in SN neuron perikarya, (2) Lewy-like dystrophic neurites in the SN and the striatum, and (3) a 53% loss of SN dopamine neurons. However, motor dysfunction was not found in either rotational or rotating rod testing. The lack of behavioral deficits, despite the significant cell loss, may reflect pathogenesis similar to that of PD, where greater than 50% losses occur before motor behavior is affected.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11916484     DOI: 10.1089/10430340252837206

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  75 in total

Review 1.  Parkinson's disease: a rethink of rodent models.

Authors:  Heather L Melrose; Sarah J Lincoln; Glenn M Tyndall; Matthew J Farrer
Journal:  Exp Brain Res       Date:  2006-04-26       Impact factor: 1.972

Review 2.  Etiology of Parkinson's disease: Genetics and environment revisited.

Authors:  Kathy Steece-Collier; Eleonora Maries; Jeffrey H Kordower
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

Review 3.  Drug targets from genetics: α-synuclein.

Authors:  Karin M Danzer; Pamela J McLean
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

4.  Definition of a molecular pathway mediating α-synuclein neurotoxicity.

Authors:  Jacqueline Burré; Manu Sharma; Thomas C Südhof
Journal:  J Neurosci       Date:  2015-04-01       Impact factor: 6.167

5.  Lentiviral vectors for the central nervous system.

Authors:  Elena Armandola
Journal:  MedGenMed       Date:  2004-09-24

6.  Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons.

Authors:  Martin Lundblad; Mickael Decressac; Bengt Mattsson; Anders Björklund
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

7.  Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.

Authors:  Christophe Lo Bianco; Bernard L Schneider; Matthias Bauer; Ali Sajadi; Alexis Brice; Takeshi Iwatsubo; Patrick Aebischer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-02       Impact factor: 11.205

Review 8.  Molecular mechanisms of alpha-synuclein neurodegeneration.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  Biochim Biophys Acta       Date:  2008-10-09

9.  Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates.

Authors:  Hemraj B Dodiya; Tomas Bjorklund; James Stansell; Ronald J Mandel; Deniz Kirik; Jeffrey H Kordower
Journal:  Mol Ther       Date:  2009-09-22       Impact factor: 11.454

10.  Tau expression levels from various adeno-associated virus vector serotypes produce graded neurodegenerative disease states.

Authors:  Ronald L Klein; Robert D Dayton; Jason B Tatom; Cynthia G Diaczynsky; Michael F Salvatore
Journal:  Eur J Neurosci       Date:  2008-04       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.